home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

14.26 +0.77 (+5.71%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

20 21 Next >

Is It Too Late to Buy Intellia Therapeutics Stock? ↗

January 27, 2024

2024 could be an important year for the biotech.

Via The Motley Fool

3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024 ↗

January 22, 2024

Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune.

Via InvestorPlace

Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics ↗

January 21, 2024

Both companies are going to continue doing high-impact science in 2024.

Via The Motley Fool

The Top Healthcare Stocks to Buy With $100 ↗

January 13, 2024

These companies are shaping the healthcare of tomorrow.

Via The Motley Fool

Voyager Therapeutics stock pops 30% on deal with Novartis

January 08, 2024

Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took

Via MarketBeat

Analyst Ratings for Intellia Therapeutics ↗

November 10, 2023

Via Benzinga

Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics ↗

January 08, 2024

These two are at very different stages of the clinical trials process.

Via The Motley Fool

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 ↗

January 08, 2024

Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.

Via The Motley Fool

AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts ↗

January 05, 2024

AlloVir layoffs are coming for 95% of the company's employees as a way to reduce costs and preserve cash after failed clinical trials.

Via InvestorPlace

Topics Workforce

Why Is Medical Properties Trust (MPW) Stock Down 31% Today? ↗

January 05, 2024

Medical Properties Trust stock is falling hard on Friday as investors in MPW react to a rent repayment plan with Steward Health Care System.

Via InvestorPlace

Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts ↗

January 05, 2024

Intellia Therapeutics layoffs are in the news on Friday as the biotech company prepares to cut its total workforce by 15% to reduce costs.

Via InvestorPlace

Topics Workforce

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics ↗

December 31, 2023

Curing rare inherited illnesses could be a lucrative business model.

Via The Motley Fool

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Via MarketBeat

5 Beaten-Down Stocks That Could Soar in 2024 ↗

December 16, 2023

These players may offer your portfolio a lift as early as next year. But most importantly, they could excel over time.

Via The Motley Fool

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Via InvestorPlace

Could Intellia Therapeutics Become the Next CRISPR Therapeutics? ↗

December 12, 2023

Intellia is approaching the finish line.

Via The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market ↗

November 28, 2023

These stocks may take off in a market favoring growth.

Via The Motley Fool

Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 20, 2023

Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 17, 2023

Via Benzinga

Why Intellia Therapeutics Stock Is Surging Tuesday ↗

November 14, 2023

Intellia Therapeutics Inc (NYSE: NTLA) shares are trading higher Tuesday after the company announced it received European Union orphan d

Via Benzinga

Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock ↗

November 13, 2023

Via Benzinga

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

Via InvestorPlace

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years ↗

November 02, 2023

Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.

Via The Motley Fool

Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy? ↗

October 28, 2023

There's more to being a good investment than doing groundbreaking science.

Via The Motley Fool

3 Stocks Cathie Wood Is Buying That Should Be on Your List Too ↗

October 23, 2023

The three companies are positioned to benefit from red-hot trends.

Via The Motley Fool

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time ↗

October 21, 2023

Wood is going all in on gene editing.

Via The Motley Fool

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com